%0 Journal Article
%A Garranzo, Marco
%A Segura, José
%A Beltrán, David
%A Rodríguez Gómez, Juan Miguel
%A Orgaz Martín, Belén
%A Arroyo Rodríguez, Rebeca
%A Alba Rubio, Claudio
%A Fernández Álvarez, Leonides
%T A randomized pilot trial assessing the reduction of gout episodes in hyperuricemic patients by oral administration of Ligilactobacillus salivarius CECT 30632, a strain with the ability to degrade purines
%D 2023
%@ 1664-302X
%U https://hdl.handle.net/20.500.14352/93808
%X Hyperuricemia and gout are receiving an increasing scientific and medical attention because of their relatively high prevalence and their association with relevant co-morbidities. Recently, it has been suggested that gout patients have an altered gut microbiota. The first objective of this study was to investigate the potential of some <jats:italic>Ligilactobacillus salivarius</jats:italic> strains to metabolize purine-related metabolites. The second objective was to evaluate the effect of administering a selected potential probiotic strain in individuals with a history of hyperuricemia.</jats:p></jats:sec><jats:sec><jats:title>Methods</jats:title><jats:p>Inosine, guanosine, hypoxanthine, guanine, xanthine, and uric acid were identified and quantified by high-performance liquid chromatography analysis. The uptake and biotransformation of these compounds by a selection of <jats:italic>L. salivarius</jats:italic> strains were assessed using bacterial whole cells and cell-free extracts, respectively. The efficacy of <jats:italic>L. salivarius</jats:italic> CECT 30632 to prevent gout was assessed in a pilot randomized controlled clinical trial involving 30 patients with hyperuricemia and a history of recurrent gout episodes. Half of the patients consumed <jats:italic>L. salivarius</jats:italic> CECT 30632 (9 log<jats:sub>10</jats:sub> CFU/day; probiotic group; <jats:italic>n</jats:italic> = 15) for 6 months while the remaining patients consumed allopurinol (100–300 mg/daily; control group; <jats:italic>n</jats:italic> = 15) for the same period. The clinical evolution and medical treatment received by the participants were followed, as well as the changes in several blood biochemical parameters.</jats:p></jats:sec><jats:sec><jats:title>Results</jats:title><jats:p>L. salivarius CECT 30632 was the most efficient strain for inosine (100%), guanosine (100%) and uric acid (50%) conversion and, therefore, it was selected for the pilot clinical trial. In comparison with the control group, administration of <jats:italic>L. salivarius</jats:italic> CECT 30632 resulted in a significant reduction in the number of gout episodes and in the use of gout-related drugs as well as an improvement in some blood parameters related to oxidative stress, liver damage or metabolic syndrome.</jats:p></jats:sec><jats:sec><jats:title>Conclusion</jats:title><jats:p>Regular administration of <jats:italic>L. salivarius</jats:italic> CECT 30632 reduced serum urate levels, the number of gout episodes and the pharmacological therapy required to control both hyperuricemia and gout episodes in individuals with a history of hyperuricemia and suffering from repeated episodes of gout.
%~